Evidence map›Paper›PMID 41218854›Full record

ArticleJournal for immunotherapy of cancer2025

Mapping B cells and the immune landscape of tertiary lymphoid structures reveals their clinical impact in neuroblastoma.

Ombretta Melaiu, Marco Chierici, Paula Gragera, Nicolò Lazzaro, Lucia L Petrilli, Judith Wienke, Francisca J Bergsma, Bronte Manouk Verhoeven, Cristiano De Stefanis, Valentina D'Oria and 11 more

Abstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. B cells in cancer: functions, mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2026
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Ombretta MelaiuDepartment of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Marco Chierici *Data Science for Health, Fondazione Bruno Kessler Research Center, Trento, Italy.
Paula Gragera *Department of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Nicolò LazzaroData Science for Health, Fondazione Bruno Kessler Research Center, Trento, Italy.
Lucia L PetrilliDepartment of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Judith WienkePrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Francisca J BergsmaPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Bronte Manouk VerhoevenDivision of Pediatric Oncology and Pediatric Surgery, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Cristiano De StefanisDepartment of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Valentina D'OriaDepartment of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Maria C BenedettiDepartment of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Giovanni BarillariDepartment of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, Rome, Italy.
Rita AlaggioDepartment of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Maria Antonietta De IorisDepartment of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Maria VinciDepartment of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Ninib BaryawnoDivision of Pediatric Oncology and Pediatric Surgery, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Rita CarsettiDepartment of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Giuseppe JurmanData Science for Health, Fondazione Bruno Kessler Research Center, Trento, Italy.
Jan J MolenaarPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Franco LocatelliDepartment of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Doriana FruciDepartment of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy doriana.fruci@opbg.net.ORCID http://orcid.org/0000-0003-3388-7296

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmunotherapy has transformed cancer treatment, highlighting the importance of effective antitumor immunity to fight cancer. However, its success in pediatric cancer remains limited, underscoring the urgent need to identify new immunotherapeutic targets. In this study, we explored the clinical relevance of B cells and tertiary lymphoid structures (TLS) in neuroblastoma (NB), a pediatric tumor with a heterogeneous immune landscape.

methodsWe analyzed 87 treatment-naïve NB specimens, spanning both localized and metastatic disease previously characterized for T-cell and dendritic cell (DC) infiltration. B cells were detected by immunohistochemistry, and plasma cells were quantified using multiple immunofluorescence. Spatial organization and functional status of immune cells within TLSs were assessed by imaging mass cytometry using a 29-antibody panel. In parallel, gene expression profiles were obtained through NanoString PanCancer Immune Profiling and further validated using publicly available bulk and single-cell RNA-sequencing data from untreated and treated NB samples. These transcriptomic datasets were used to support protein-level findings and to identify prognostic gene signatures.

resultsB-cell infiltration in NB tumors strongly correlated with the presence of T cells and DCs at both protein and transcriptomic levels, and was associated with improved prognosis. Similar to other solid tumors, B cells in NB were either scattered throughout the tumor or organized into TLSs of varying maturity. Spatial proteomic and transcriptomic analyses revealed that localized tumors often contain mature TLSs, with functional B cells able to antigen presentation and immunoglobulin expression, alongside high cytotoxic T cells. In contrast, metastatic tumors primarily exhibited immature TLSs, with evidence of B-cell and T-cell dysfunction. Importantly, we identified gene signatures associated with B cells and TLSs that not only predicted survival in NB but were also prognostic in multiple adult cancers.

conclusionsOur findings highlight a central role for B cells and TLSs in shaping the immune microenvironment of NB. Their presence and maturation status are linked to clinical outcome, suggesting their potential as prognostic biomarkers and targets for novel immunotherapeutic strategies in pediatric oncology.

Indexed as

B-LymphocytesNeuroblastomaTertiary Lymphoid StructuresChildChild, PreschoolFemaleHumansInfantLymphocytes, Tumor-InfiltratingMalePrognosisTumor MicroenvironmentB cellImmunotherapyNeuroendocrine and Adrenal TumorTumor infiltrating lymphocyte - TILTumor microenvironment - TME

Identifiers

PMID41218854
PMCPMC12606491

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.